Short answer
Xenon Pharmaceuticals Inc. (XENE) filed an 8-K current report with the SEC on February 26, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Full-year 2025 financial results announced Feb 26, 2026.
Xenon Pharmaceuticals Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Full-year 2025 financial results announced Feb 26, 2026
- Complete figures in Exhibit 99.1 press release attachment
Item 7.01 · Regulation FD Disclosure
- Reg FD disclosure designating official investor communication channels: SEC filings, press releases, website, and social media
- Investors should monitor @XenonPharma (X/Twitter), LinkedIn, and Facebook for potentially material updates between formal filings
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Xenon Pharmaceuticals Inc. 8-K filings
Get the next XENE 8-K as it lands
Follow XENE for push alerts, or ask the research agent what this filing means.